Results 51 to 60 of about 23,909 (233)
Mechanisms of SCN2A loss of function do not predict presence or phenotype of epilepsy
Epilepsia, EarlyView.Abstract Objective SCN2A loss‐of‐function (LoF) variants are associated with epilepsy (onset age ≥ 3 months), intellectual disability (ID), and autism spectrum disorder (ASD). Despite numerous identified variants and the description of phenotypic subgroups, relationships between Nav1.2 channel dysfunction and clinical phenotypes remain unclear.
Marsha Tan +23 more
wiley +1 more source
Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy
Frontiers in Neurology, 2019 Objective: Controlled and open label trials have demonstrated efficacy of cannabidiol for certain epileptic encephalopathies. However, plant derived cannabidiol products have been used almost exclusively. Efficacy of synthetically derived cannabidiol has
Kerstin A. Klotz +6 more
doaj +1 more source
Hemp in Animal Diets—Cannabidiol
Animals, 2022 In recent years, interest in hemp use has grown owing to its chemical and medicinal properties. Several parts of this plant, such as seeds, leaves, flowers, and stems are used in medicine, industry, and environmental preservation.
Sepideh Fallahi +2 more
doaj +1 more source
Epilepsia, EarlyView.Abstract Objective Dravet syndrome (DS) is the prototypic developmental and epileptic encephalopathy, characterized by drug‐resistant seizures, developmental slowing, and many other morbidities. Detailed characterization of behavioral phenotypes and social–emotional skill development are limited.
Ingrid E. Scheffer +26 more
wiley +1 more source
In vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin [PDF]
, 2021 Margarita Zhelyazkova +3 more
openalex +1 more source
Precision therapies for genetic epilepsies in 2025: Promises and pitfalls
Epilepsia Open, EarlyView.Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang +3 more
wiley +1 more source
Orthogonal Strategies for Profiling Potential Cellular Targets of Anandamide and Cannabidiol [PDF]
, 2023 Guanghui Tang +5 more
openalex +1 more source
Epileptic drop attacks: More than just atonic seizures
Epilepsia Open, EarlyView.Abstract “Drop attacks” are not officially defined by the International League Against Epilepsy. Seizures are characterized by a sudden loss of control over the trunk and posture, leading to falls and injuries, and resolving within a few seconds. Accurately diagnosing the type of seizure is usually difficult due to limitations in clinical documentation
Tomonori Ono +3 more
wiley +1 more source
Predictors of etiology and drug resistance in children with new‐onset focal seizures
Epilepsia Open, EarlyView.Abstract Objective To examine the clinical features of new‐onset focal seizures in children and investigate clinical associations and predictors of underlying etiology and drug resistance. Methods Data were gathered from The Children's Hospital at Westmead admissions for patients aged 1 month to 18 years who presented with new‐onset focal seizures ...
Byoung Chan Lee +7 more
wiley +1 more source
Stiripentol use in Dravet syndrome patients in the USA: Results of a real‐world study
Epilepsia Open, EarlyView.Abstract Objective Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy with a high seizure burden and mortality risk. Stiripentol, one of the first DS‐specific therapies, received FDA approval in 2018 but its real‐world use and impact post‐approval in the USA remain insufficiently characterized.
Elaine Wirrell +11 more
wiley +1 more source